Group 1 - The company, Taimei Medical Technology, has established a partnership agreement to form a partnership enterprise with an initial total investment of RMB 227.27 million from various partners [1] - The investment contributions from the partners include RMB 70 million from the company, RMB 30 million from Taimei Zhiyan, RMB 100 million from Jiaxing Chantuo, and smaller amounts from individual partners [1] - The partnership enterprise will primarily invest in companies located in the Jiaxing Economic and Technological Development Zone [1] Group 2 - The board believes that the establishment of the partnership enterprise will allow the company to deeply engage in the research and development of innovative drug pipelines [2] - The company aims to standardize and modularize its digital pharmaceutical R&D solutions for early to growth-stage innovative drug development pipelines, potentially sharing in the excess returns from successful drug development [2] - By holding pipeline rights through the partnership, the company can participate in early clinical trials, thus avoiding the complexities and long-term risks associated with traditional equity investments [2]